New drug combo aims to fight bladder cancer without removing the bladder
NCT ID NCT06470282
Summary
This study is testing a new combination of two cancer drugs (enfortumab vedotin and pembrolizumab) given alongside targeted radiation therapy. The goal is to see if this approach can effectively control muscle-invasive bladder cancer for patients who are not candidates for, or who wish to avoid, surgery to remove their bladder. Researchers will first find the safest dose and then see how well the treatment works at keeping the cancer in check and preserving the patient's bladder.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.